Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-03-27 6:17 pm Sale | 2024-11-18 | 13D | Syros Pharmaceuticals, Inc. SYRS | Samsara BioCapital, L.P. | 707,114 2.600% | -1,808,409 (-71.89%) | Filing History |
| 2025-02-14 4:09 pm Sale | 2024-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | Point72 Asset Management, L.P. | 496 0.000% | -1,471,275 (-99.97%) | Filing History |
| 2025-02-14 10:10 am Sale | 2024-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | Avidity Partners Management LP | 2,048,020 7.600% | -809,553 (-28.33%) | Filing History |
| 2025-02-14 08:41 am Sale | 2024-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | Deep Track Capital, LP | 0 0.000% | -699,281 (Position Closed) | Filing History |
| 2025-02-12 4:30 pm Sale | 2024-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | Invus Public Equities, L.P. | 1,063,829 3.800% | -2,587,372 (-70.86%) | Filing History |
| 2025-02-12 09:41 am Sale | 2024-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | ADAGE CAPITAL PARTNERS GP L.L.C. | 531,914 1.980% | -2,092,070 (-79.73%) | Filing History |
| 2024-11-14 5:28 pm Purchase | 2024-09-30 | 13G | Syros Pharmaceuticals, Inc. SYRS | Avidity Partners Management LP | 2,857,573 9.900% | 195,367 (+7.34%) | Filing History |
| 2024-11-14 5:24 pm Purchase | 2024-09-30 | 13G | Syros Pharmaceuticals, Inc. SYRS | Bain Capital Life Sciences Fund II, L.P. | 2,750,151 11.000% | 343 (+0.01%) | Filing History |
| 2024-11-14 5:05 pm Sale | 2024-09-30 | 13G | Syros Pharmaceuticals, Inc. SYRS | Blue Owl Capital Holdings LP | 515,855 1.920% | -977,397 (-65.45%) | Filing History |
| 2024-11-12 4:30 pm Purchase | 2024-09-30 | 13G | Syros Pharmaceuticals, Inc. SYRS | Invus Public Equities, L.P. | 3,651,201 9.900% | 82,359 (+2.31%) | Filing History |
| 2024-08-02 6:39 pm Purchase | 2024-07-25 | 13G | Syros Pharmaceuticals, Inc. SYRS | Invus Public Equities, L.P. | 3,568,842 9.900% | 3,568,842 (New Position) | Filing History |
| 2024-02-14 8:56 pm Purchase | 2023-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | Blue Owl Capital Holdings LP | 1,493,252 5.740% | 1,493,252 (New Position) | Filing History |
| 2024-02-13 8:22 pm Purchase | 2023-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | Avidity Partners Management LP | 2,662,206 9.900% | 472,487 (+21.58%) | Filing History |
| 2024-02-13 7:02 pm Sale | 2023-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | Ally Bridge MedAlpha Master Fund L.P. | 570,976 2.600% | -868,403 (-60.33%) | Filing History |
| 2024-02-13 6:59 pm Purchase | 2023-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | Bain Capital Life Sciences Fund II, L.P. | 2,749,808 11.000% | 625,114 (+29.42%) | Filing History |
| 2024-02-09 5:08 pm Purchase | 2023-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | Artal Participations S.a r.l | 3,568,842 9.900% | 2,105,013 (+143.80%) | Filing History |
| 2024-02-07 07:09 am Purchase | 2023-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | ADAGE CAPITAL PARTNERS GP L.L.C. | 2,623,984 9.990% | 1,370,156 (+109.28%) | Filing History |
| 2024-01-02 4:15 pm Purchase | 2023-12-21 | 13G | Syros Pharmaceuticals, Inc. SYRS | Point72 Asset Management, L.P. | 1,471,771 5.700% | 1,471,771 (New Position) | Filing History |
| 2023-12-26 5:19 pm Purchase | 2023-12-21 | 13D | Syros Pharmaceuticals, Inc. SYRS | Samsara BioCapital, L.P. | 2,515,523 9.500% | 909,977 (+56.68%) | Filing History |
| 2023-10-20 4:15 pm Purchase | 2023-01-15 | 13D | Syros Pharmaceuticals, Inc. SYRS | Samsara BioCapital, L.P. | 1,605,546 7.500% | 1,605,546 (New Position) | Filing History |